FindTrial
Sign In

A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer. - GP06

A phase II study to evaluate the efficacy of bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer. - GP06

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-002992-42-IT
Enrollment
Unknown
Registered
2007-07-09
Start date
2006-09-06
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced pancreatic cancer. MedDRA version: 9.1 Level: LLT Classification code 10033611 Term: Pancreatic carcinoma non-resectable

Interventions

Trade Name: AVASTIN*INFUS 1FL 100MG Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: BEVACIZUMAB Concentration unit: mg milligram(s) Concentration type: equal Concentrat

Sponsors

AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Age 18-75; - Zubrod Performance status 0-1; - Histologically confirmed locally advanced pancreatic cancer. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Brain or visceral metastasis; - Prior radiotherapy or chemotherapy within 5 years.

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the overall survival after 1 year of treatment with bevacizumab in combination with capecitabine and concomitant radiotherapy in patients affected by non-resectable locally advanced pancreatic cancer.;Secondary Objective: - To evaluate the incidence of serious adverse events during treatment; - To assess the objective response rate of this regimen; - To evaluate the failure free survival (FFS) after 1 year of treatment; - To assess the number of patient who undergo surgery after treament.;Primary end point(s): Overall survival.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026